Clarus Therapeutics Holdings, Inc., recently announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, Jatenzo (testosterone undecanoate).
Related posts
-
Jussie Smollett’s conviction in 2019 attack on himself is overturned
The Illinois Supreme Court on Thursday overturned actor Jussie Smollett’s conviction on charges that he staged... -
Catching up with recruiting for the Class of 2026 in the suburbs
With the IHSA football season coming to a close over the next couple of weeks, more... -
Silvy: I’ve said it before, I’ll say it again, Eberflus is not a good head coach
Matt Eberflus isn't a good head coach. You know it. I know it. Hopefully Ryan Poles...